Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Cristina Azpitarte Raposeiras"'
Autor:
Rocio Vilchez Simo, Maria Carmen Areses Manrique, María Rosario García Campelo, Cristina Azpitarte Raposeiras, Jose Muñoz Iglesias, Joaquín Martínez, Urbano Anido Herranz, F.J. Afonso, Natalia Fernández Núñez, David Arias Ron, Begoña Campos Balea, Martin Lázaro Quintela, Juan Ruiz Bañobre, Jorge García González, Margarita Amenedo Gancedo, Lucía Santomé Couto, José Luis Fírvida Pérez, Joaquin Casal Rubio, Jesús García Mata, Guillermo Alonso-Jaudenes Curbera, Iria Carou Frieiro
Publikováno v:
Journal of geriatric oncology. 12(3)
Background Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8f0359c9eb9f002de01c36c87004c8
https://pubmed.ncbi.nlm.nih.gov/33357975
https://pubmed.ncbi.nlm.nih.gov/33357975
Autor:
Juan Ruiz-Bañobre, Sergio Vázquez, María Del Carmen Areses-Manrique, Lucía Santomé, Jorge García-González, Cristina Azpitarte-Raposeiras, Noemí de Dios-Álvarez, N. Fernández-Núñez, Rosario García-Campelo, Joaquín Mosquera-Martínez, Alexandra Cortegoso, Jose L. Fírvida-Pérez, Joaquín Casal-Rubio, Margarita Amenedo, Francisco J. Afonso-Afonso
Publikováno v:
Transl Lung Cancer Res
The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd6469ae566fac2ed3db43ea72e77b3
https://pubmed.ncbi.nlm.nih.gov/32953477
https://pubmed.ncbi.nlm.nih.gov/32953477
Autor:
Natalia Fernández Núñez, Martin Lázaro Quintela, Iria Carou Frieiro, Joaquin Mosquera Martinez, Margarita Amenedo Gancedo, Joaquin Casal Rubio, Jose Muñoz Iglesias, Alexandra Sabela Cortegoso mosquera, Rocio Vilchez Simo, Urbano Anido Herranz, Jesús García Mata, Lucía Santomé Couto, Begoña Campos Balea, Mª Carmen Areses Manrique, Jorge García González, Mª Rosario García Campelo, Guillermo Alonso-Jaudenes Curbera, José Luis Fírvida Pérez, Cristina Azpitarte Raposeiras, F.J. Afonso
Publikováno v:
Translational Lung Cancer Research. 7:404-415
Background Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data of real life is lacking. This is an observational study that represents the real world experience with nivol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc7bb30d30b4aba37c3cf312d55b53a
https://doi.org/10.21037/tlcr.2018.04.03
https://doi.org/10.21037/tlcr.2018.04.03
Autor:
Rosario García-Campelo, Francisco J. Afonso-Afonso, Margarita Amenedo, Sergio Vazquez-Estevez, Ana L. González-Piñeiro, Martín Lázaro-Quintela, Ihab Abdulkader, Juan Ruiz-Bañobre, Ángel Vázquez-Boquete, Lucía Santomé, José Cameselle-Teijeiro, Cristina Azpitarte-Raposeiras, Raquel Pérez-Becerra, Jose L. Fírvida-Pérez, María Sánchez-Ares, Yolanda Rico-Rodríguez, Elena Couso, José Antúnez, Joaquín Casal-Rubio
Publikováno v:
Oncology Letters. 12:1403-1407
Identification of anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements is a standard diagnostic test in patients with advanced non-small cell lung cancer (NSCLC). The current study describes the experience of ALK rearrangement detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb3329cff9ab9e656216a11c1f567199
https://doi.org/10.3892/ol.2016.4788
https://doi.org/10.3892/ol.2016.4788
Autor:
Cristina Azpitarte Raposeiras, Noemi De Dios Alvarez, Jorge Garcia, Vanesa Varela Pose, Martin Lázaro Quintela, Victor Cebey, F.J. Afonso, Manuel Constenla, Maria Carmen Areses Manrique, Sara Agraso Busto, Margarita Amenedo, Natalia Fernández Núñez, J. L. Fírvida, Begoña Campos Balea, Juan Ruiz Bañobre, Nazaret Quiroga Veiga
Publikováno v:
Journal of Clinical Oncology. 37:e20636-e20636
e20636 Background: First or second line crizotinib has shown greater efficacy in clinical trials than chemotherapy in patients with NSCLC ALK positive and it was the first approved ALK inhibitor. However, there are limited data describing the use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::931f32177dca505fc3aa9a66449d847c
https://doi.org/10.1200/jco.2019.37.15_suppl.e20636
https://doi.org/10.1200/jco.2019.37.15_suppl.e20636
Autor:
F.J. Afonso, Nazaret Quiroga Veiga, Cristina Azpitarte Raposeiras, Joaquin Casal Rubio, Margarita Amenedo, Lucía Santomé, Rafael López, Maria Carmen Areses Manrique, Rosario Garcia Campelo, Gerardo Huidobro Vence, Joaquín Martínez, Guillermo Alonso-Jaudenes Curbera, Natalia Fernández Núñez, Urbano Anido Herranz, Rocio Vilchez Simo, Alexandra Cortegoso, Sergio Vázquez Estévez, Jesús García Mata, Juan Ruiz Bañobre, José Luis Fírvida Pérez
Publikováno v:
Journal of Clinical Oncology. 37:e20645-e20645
e20645 Background: The lung immune prognostic index (LIPI) has been proposed as a new biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 or programmed death ligand 1 therapy. In this study, we in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa744ffa139bdae4677d0bc712ca0139
https://doi.org/10.1200/jco.2019.37.15_suppl.e20645
https://doi.org/10.1200/jco.2019.37.15_suppl.e20645
Autor:
María, Sánchez-Ares, José M, Cameselle-Teijeiro, Sergio, Vázquez-Estévez, Martín, Lázaro-Quintela, Ángel, Vázquez-Boquete, Francisco J, Afonso-Afonso, Joaquín, Casal-Rubio, Ana L, González-Piñeiro, Yolanda, Rico-Rodríguez, José L, Fírvida-Pérez, Juan, Ruíz-Bañobre, Elena, Couso, Lucía, Santomé, Raquel, Pérez-Becerra, Rosario, García-Campelo, Margarita, Amenedo, Cristina, Azpitarte-Raposeiras, José, Antúnez, Ihab, Abdulkader
Publikováno v:
Oncology Letters
Identification of anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements is a standard diagnostic test in patients with advanced non-small cell lung cancer (NSCLC). The current study describes the experience of ALK rearrangement detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a91cc57feeecad6c7067ed85316fde58
https://pubmed.ncbi.nlm.nih.gov/27446444
https://pubmed.ncbi.nlm.nih.gov/27446444